A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body — STAR-221  

Advanced Upper Gastrointestinal Tract Adenocarcinoma Clinical Trial

Official title: A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Status Recruiting

Clinical Trial Summary

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma

• NCT number: NCT05568095
• Study type: Interventional
• Source: Arcus Biosciences, Inc.
• Contact: Medical Director
• Phone: +1-510-462-3330
• Email: ClinicalTrials@arcusbio.com
• Status: Recruiting
• Phase: Phase 3
• Start date: November 21, 2022
• Completion date: January 2027